1.
Clin Infect Dis
; 72(11): 2032-2034, 2021 06 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32697327
RESUMO
Abacavir is a potential option for prophylaxis and early treatment of human immunodeficiency virus (HIV), but no data are available in neonates. Ten neonates administered a single abacavir dose of 8 mg/kg before 15 days of life had substantially higher exposures than those reported in infants and children, with no reported adverse events.
Assuntos
Fármacos Anti-HIV , Infecções por HIV , Fármacos Anti-HIV/uso terapêutico , Criança , Didesoxinucleosídeos/uso terapêutico , HIV , Infecções por HIV/tratamento farmacológico , Humanos , Lactente , Recém-Nascido
2.
J Pediatric Infect Dis Soc
; 10(2): 201-204, 2021 Mar 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32448902
RESUMO
Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB. CLINICAL TRIALS REGISTRATION: NCT01751568.